News

Glenmark Pharmaceuticals Limited will close its trading window for designated persons, including directors, key managerial personnel, and immediate relatives, starting October 1, 2026, and continuing until the declaration of the company’s unaudited financial results for the second quarter ended September 30, 2026, and forty-eight hours thereafter.

Glenmark Pharmaceuticals announced that the 48th Annual General Meeting(AGM) of the company will be held on 11 September 2026.

Net profit of Glenmark Pharmaceuticals rose 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Sales rose 28.52% to Rs 3931.73 crore in the quarter ended June 2026 as against Rs 3059.33 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales3931.733059.33 29 OPM %20.4718.98 - PBDT816.56548.73 49 PBT643.39418.81 54 NP482.9246.87 930 Powered by Capital Market - Live News

Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS� (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS� is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 July 2026.